Herbimycin A (Synonyms: Antibiotic TAN 420F, NSC 305978) |
| カタログ番号GC15000 |
アンサマイシン系抗生物質であるハービマイシン A は、Src ファミリーのキナーゼ阻害剤として作用します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70563-58-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Herbimycin A is an antibiotic and a selective inhibitor of non-receptor tyrosine kinases [1].
Antibiotics are a type of antimicrobial used in the treatment of bacterial infection. Non-receptor tyrosine kinases (nRTKs) are cytoplasmic enzymes and catalyse the transfer of a phosphate group from a nucleoside triphosphate donor to tyrosine residues in proteins.
Herbimycin A is a selective non-receptor tyrosine kinases inhibitor. Herbimycin A bound to the reactive SH domains of p60v-src and p210BCR-ABL and inactivated their activity [1].
In a retinopathy prematurity rat model, Herbimycin A inhibited capillary tube formation and bovine retinal microvascular endothelial cell proliferation induced by vascular endothelial growth factor in a dose-dependent way. Also, Herbimycin A reduced pre-retinal neovascularization by 63% and 41% in oxygen-treated rats and herbimycin-injected eyes, respectively [2]. In rats exposed to heat stress, Herbimycin A exhibited thermotolerance and significantly reduced apoptosis of hepatocytes. Also, Herbimycin A inhibited caspase-3 activation [3].
References:
[1]. Fukazawa H, Uehara Y, Murakami Y, et al. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett, 1994, 340(3): 155-158.
[2]. McCollum GW, Rajaratnam VS, Bullard LE, et al. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity. Exp Eye Res, 2004, 78(5): 987-995.
[3]. Sachidhanandam SB, Lu J, Low KS, et al. Herbimycin A attenuates apoptosis during heat stress in rats. Eur J Pharmacol, 2003, 474(1): 121-128.
| Cas No. | 70563-58-5 | SDF | |
| 同義語 | Antibiotic TAN 420F, NSC 305978 | ||
| Chemical Name | (4Z,6E,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | ||
| Canonical SMILES | O=C(C(NC1=O)=C2)C([C@@H]([C@@H](C)C[C@@H]([C@@H]([C@@H](C)/C=C(C)/[C@@H]([C@H](/C=C/C=C1/C)OC)OC(N)=O)OC)OC)OC)=CC2=O | ||
| Formula | C30H42N2O9 | M.Wt | 574.67 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7401 mL | 8.7006 mL | 17.4013 mL |
| 5 mM | 348 μL | 1.7401 mL | 3.4803 mL |
| 10 mM | 174 μL | 870.1 μL | 1.7401 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *